A Phase 1, Dose Escalation Study of Plerixafor in Combination With Induction and Consolidation Chemotherapy in Patients With Relapsed Acute Myeloid Leukemia.
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2016
At a glance
- Drugs Plerixafor (Primary) ; Cytarabine; Daunorubicin; Granulocyte colony-stimulating factors
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms PRIMAL
- 10 Jun 2017 Biomarkers information updated
- 20 Aug 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Oct 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov